Results 251 to 260 of about 188,451 (293)
Some of the next articles are maybe not open access.
Cancer, 1978
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +2 more sources
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +2 more sources
Deutsche medizinische Wochenschrift (1946), 2018
The advent of tyrosine kinase inhibitors (TKI) has improved prognosis and outcome of patients with chronic myelogenous leukemia (CML) considerably. In comparison to imatinib, first line use of second generation inhibitors nilotinib, dasatinib and bosutinib lead to faster and deeper molecular remissions accompanied by a novel adverse event profile ...
Chetasi Talati, Javier Pinilla-Ibarz
openaire +3 more sources
The advent of tyrosine kinase inhibitors (TKI) has improved prognosis and outcome of patients with chronic myelogenous leukemia (CML) considerably. In comparison to imatinib, first line use of second generation inhibitors nilotinib, dasatinib and bosutinib lead to faster and deeper molecular remissions accompanied by a novel adverse event profile ...
Chetasi Talati, Javier Pinilla-Ibarz
openaire +3 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2006
In the therapy of chronic myelogenous leukemia (CML), interferon (IFN) brought about a big progress resulting in the good hematologic as well as cytogenetic response and prolongation of survival. Recently, imatinib, the BCR/ABL antagonist, took over the first choice drug of the treatment CML.
openaire +3 more sources
In the therapy of chronic myelogenous leukemia (CML), interferon (IFN) brought about a big progress resulting in the good hematologic as well as cytogenetic response and prolongation of survival. Recently, imatinib, the BCR/ABL antagonist, took over the first choice drug of the treatment CML.
openaire +3 more sources
[Chronic myelogenous leukemia].
Der Internist, 2015The advent of tyrosine kinase inhibitors (TKI) has improved the prognosis and outcome of patients with chronic myelogenous leukemia (CML) considerably. Compared with imatinib, the first-line use of second-generation inhibitors nilotinib and dasatinib has led to faster and deeper molecular remissions accompanied by a differential adverse effect profile.
A, Hochhaus +3 more
openaire +3 more sources
JAMA, 1983
A 50-year-old man had chronic myelogenous leukemia and entered a blast crisis that was both morphologically and histochemically lymphoid. The blasts contained terminal deoxyribonucleotidyl transferase and expressed lymphoblastic leukemia-associated antigen. He rapidly entered remission with vincristine sulfate and prednisone therapy.
openaire +1 more source
A 50-year-old man had chronic myelogenous leukemia and entered a blast crisis that was both morphologically and histochemically lymphoid. The blasts contained terminal deoxyribonucleotidyl transferase and expressed lymphoblastic leukemia-associated antigen. He rapidly entered remission with vincristine sulfate and prednisone therapy.
openaire +1 more source
Journal of the American Medical Association, 1931
Any discussion of the value of irradiation in myelogenous leukemia must be based on a knowledge of the natural course of this disease. The duration of life in untreated cases is not well known; statistics are few, and the following factors make difficult the determination of this point: The disease is comparatively rare, and the literature contains ...
openaire +2 more sources
Any discussion of the value of irradiation in myelogenous leukemia must be based on a knowledge of the natural course of this disease. The duration of life in untreated cases is not well known; statistics are few, and the following factors make difficult the determination of this point: The disease is comparatively rare, and the literature contains ...
openaire +2 more sources
2014
The impact of age as a poor prognostic factor in chronic myeloid leukemia (CML) has been well described. In the interferon era, elderly patients diagnosed with CML in chronic phase had shorter survival compared to younger patients. With the advent of targeted therapy with imatinib, studies described consistently improved responses in elderly late ...
Andreas Hochhaus, Susanne Saussele
openaire +1 more source
The impact of age as a poor prognostic factor in chronic myeloid leukemia (CML) has been well described. In the interferon era, elderly patients diagnosed with CML in chronic phase had shorter survival compared to younger patients. With the advent of targeted therapy with imatinib, studies described consistently improved responses in elderly late ...
Andreas Hochhaus, Susanne Saussele
openaire +1 more source
Role of cancer immunology in chronic myelogenous leukemia.
Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis, 2019H. Ureshino, T. Shindo, S. Kimura
semanticscholar +1 more source
Hematology/Oncology Clinics of North America, 2004
Hagop M. Kantarjian, Moshe Talpaz
openaire +2 more sources
Hagop M. Kantarjian, Moshe Talpaz
openaire +2 more sources